News Focus
News Focus
icon url

NewMoney

05/06/20 8:20 AM

#143566 RE: KMBJN #143565

Good luck. Make money.
icon url

loanranger

05/06/20 9:23 AM

#143567 RE: KMBJN #143565

"NNVC hopefully will go much quicker on second and third drug if using same nanomicelle backbone .. Just design and synthesize new ligand and attachment method and have a new drug."

That's the benefit that was mentioned most when I first arrived here. I think your sentence would be a little more relatable if it ended with the word "candidate".
icon url

arvitar

05/06/20 12:43 PM

#143570 RE: KMBJN #143565

The fact remains, in all of human history there has never been a single instance of a management team first failing for 15 years to get a single preclinical candidate IND-approved, and then suddenly accomplishing that feat.

There's no reason to believe that NNVC will be the first.

Indeed, given the age and unremarkable careers of its management team, there's plenty of reason to believe that NNVC won't be the first to set such historic precedent.